Nutritional Advice El Mondo
Objectives:
The questions remained if mortality benefits with dexamethasone seen in patients with coronavirus disease 2019 (COVID-19) also extend to other systemic corticosteroids such as methylprednisolone. Therefore, this review article has been conducted.
Does methylprednisolone decrease mortality from COVID-19?
Study design:
This review article included 5 RCTs.
Results and conclusions:
The investigators found the pooled OR for all-cause mortality was 0.64 [95% CI = 0.29 to 1.43, n = 652] comparing methylprednisolone with the control, indicating no mortality benefits.
A similar finding was noted with a subgroup analysis including 4 trials that used low-dose methylprednisolone.
The investigators found, however, the only trial that administered high doses of methylprednisolone indicated a statistically significant mortality benefit [OR = 0.08, 95% CI = 0.02 to 0.42].
The investigators concluded that a short duration (3 to 5 days) pulse therapy of high-dose methylprednisolone can be a promising alternative to the low-dose dexamethasone therapy in severely ill patients with COVID-19 to prevent deaths.
Original title:
Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials by Hasan SS, Kow CS, […], Merchant HA.
Link:
https://pubmed.ncbi.nlm.nih.gov/33945381/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.